Cardioplegia IV Solution Recalled Due to Sterility Assurance Deficiency
Central Admixture Pharmacy Services has recalled Cardioplegia Solution due to lacking sterility assurance and insufficient validation data for decontamination cycles. The recall affects 148 bags distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving inadequate sterility assurance for a sterile injectable product. No reported illnesses, deaths, or injuries are documented. The score reflects the seriousness of a potential sterility defect in a critical-use injectable without confirmed harm.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling Cardioplegia Solution, 70 mEq K, Induction 8:1, a high potassium IV solution in 300 mL bags. The product (NDC: 72196-0214-1) was distributed nationwide in the USA. Two lot numbers are affected: Lot 36-253954 (expiration 7/20/2023) and Lot 36-256032 (expiration 7/28/2023). A total of 148 bags are subject to this recall.
The recall was initiated due to lack of assurance of sterility. The manufacturer has not provided adequate validation data for the decontamination cycles used in the sterilization process, raising concerns about whether the product is sterile and safe for use.
This product is an intravenous (IV) solution intended for use in hospital settings. Healthcare facilities, pharmacies, and medical professionals that received the affected lot numbers should be aware of this recall.
Healthcare facilities and medical professionals should immediately quarantine and discontinue use of the affected product lots. Anyone with questions or concerns should contact the FDA or the recalling manufacturer, Central Admixture Pharmacy Services, Inc.
The recalled product
- Product
- CARDIOPLEGIA SOLUTION, 70 mEq K, Induction 8:1, non-enriched, High Potassium, IV Bag, Total Volume = 300 mL, RX only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Pheonix, AZ 85043, NDC: 72196-0214-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Affected units
- 148
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot: 36-253954
- Exp. 7/20/2023
- 36-256032
- Exp. 7/28/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 95 recalled by Central Admixture Pharmacy Services, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 95 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services, Inc.
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15